Biopharmaceutical company Halozyme Therapeutics (HALO) has entered into a global collaboration and licensing agreement with ViiV Healthcare to further the development of ultra-long-acting …
Halozyme Therapeutics, Inc. (NASDAQ:HALO) provided program updates and its annual financial guidance at the 35th annual JP Morgan Healthcare Conference.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its HALO …
Halozyme Therapeutics, Inc. (NASDAQ:HALO) investors are heading for the hills after the drug maker announced that AbbVie has discontinued a development program using the …
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced an agreement to collaborate on clinical studies evaluating up to eight different tumor types beginning in 2017.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported financial results and recent highlights for the third quarter ended September 30.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that its investigational drug, PEGPH20, and a companion diagnostic assay for assessment of hyaluronan (HA) under development by Ventana …
Halozyme Therapeutics, Inc. (NASDAQ:HALO), an oncology biotech developing novel oncology and drug-delivery therapies, today named biotech veteran Mark J.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that Eisai Inc.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that it has resumed the enrollment and dosing of patients in its ongoing Phase 1b trial evaluating its …